These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

291 related items for PubMed ID: 22401489

  • 1. Sponsorship, antidepressant dose, and outcome in major depressive disorder: meta-analysis of randomized controlled trials.
    Sinyor M, Schaffer A, Smart KA, Levitt AJ, Lanctôt KL, Grysman NH.
    J Clin Psychiatry; 2012 Feb; 73(2):e277-87. PubMed ID: 22401489
    [Abstract] [Full Text] [Related]

  • 2. Does the presence of an open-label antidepressant treatment period influence study outcome in clinical trials examining augmentation/combination strategies in treatment partial responders/nonresponders with major depressive disorder?
    Iovieno N, Papakostas GI.
    J Clin Psychiatry; 2012 May; 73(5):676-83. PubMed ID: 22569112
    [Abstract] [Full Text] [Related]

  • 3. Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses.
    Sinyor M, Levitt AJ, Cheung AH, Schaffer A, Kiss A, Dowlati Y, Lanctôt KL.
    J Clin Psychiatry; 2010 Mar; 71(3):270-9. PubMed ID: 20122371
    [Abstract] [Full Text] [Related]

  • 4. Correlation between different levels of placebo response rate and clinical trial outcome in major depressive disorder: a meta-analysis.
    Iovieno N, Papakostas GI.
    J Clin Psychiatry; 2012 Oct; 73(10):1300-6. PubMed ID: 23140647
    [Abstract] [Full Text] [Related]

  • 5. Complementary and alternative medicine for major depressive disorder: a meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relative to standard antidepressants.
    Freeman MP, Mischoulon D, Tedeschini E, Goodness T, Cohen LS, Fava M, Papakostas GI.
    J Clin Psychiatry; 2010 Jun; 71(6):682-8. PubMed ID: 20573327
    [Abstract] [Full Text] [Related]

  • 6. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
    Khin NA, Chen YF, Yang Y, Yang P, Laughren TP.
    J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
    [Abstract] [Full Text] [Related]

  • 7. High-frequency repetitive transcranial magnetic stimulation accelerates and enhances the clinical response to antidepressants in major depression: a meta-analysis of randomized, double-blind, and sham-controlled trials.
    Berlim MT, Van den Eynde F, Daskalakis ZJ.
    J Clin Psychiatry; 2013 Feb; 74(2):e122-9. PubMed ID: 23473357
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials.
    Tedeschini E, Levkovitz Y, Iovieno N, Ameral VE, Nelson JC, Papakostas GI.
    J Clin Psychiatry; 2011 Dec; 72(12):1660-8. PubMed ID: 22244025
    [Abstract] [Full Text] [Related]

  • 9. Antidepressants for major depressive disorder and dysthymic disorder in patients with comorbid alcohol use disorders: a meta-analysis of placebo-controlled randomized trials.
    Iovieno N, Tedeschini E, Bentley KH, Evins AE, Papakostas GI.
    J Clin Psychiatry; 2011 Aug; 72(8):1144-51. PubMed ID: 21536001
    [Abstract] [Full Text] [Related]

  • 10. Placebo-controlled, antidepressant clinical trials cannot be shortened to less than 4 weeks' duration: a pooled analysis of randomized clinical trials employing a diagnostic odds ratio-based approach.
    Tedeschini E, Fava M, Papakostas GI.
    J Clin Psychiatry; 2011 Jan; 72(1):98-113. PubMed ID: 21208576
    [Abstract] [Full Text] [Related]

  • 11. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA, Padmanabhan SK, Groark J, Brisard C, Farrington D.
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [Abstract] [Full Text] [Related]

  • 12. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
    Pigott TA, Prakash A, Arnold LM, Aaronson ST, Mallinckrodt CH, Wohlreich MM.
    Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
    [Abstract] [Full Text] [Related]

  • 13. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
    Perahia DG, Pritchett YL, Kajdasz DK, Bauer M, Jain R, Russell JM, Walker DJ, Spencer KA, Froud DM, Raskin J, Thase ME.
    J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
    [Abstract] [Full Text] [Related]

  • 14. Can people with nonsevere major depression benefit from antidepressant medication?
    Stewart JA, Deliyannides DA, Hellerstein DJ, McGrath PJ, Stewart JW.
    J Clin Psychiatry; 2012 Apr; 73(4):518-25. PubMed ID: 22226407
    [Abstract] [Full Text] [Related]

  • 15. Duloxetine in the treatment of major depressive disorder: comparisons of safety and tolerability in male and female patients.
    Stewart DE, Wohlreich MM, Mallinckrodt CH, Watkin JG, Kornstein SG.
    J Affect Disord; 2006 Aug; 94(1-3):183-9. PubMed ID: 16780958
    [Abstract] [Full Text] [Related]

  • 16. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
    Wohlreich MM, Mallinckrodt CH, Prakash A, Watkin JG, Carter WP.
    Depress Anxiety; 2007 Aug; 24(1):41-52. PubMed ID: 16845641
    [Abstract] [Full Text] [Related]

  • 17. Meta-analysis of efficacy and treatment-emergent suicidality in adults by psychiatric indication and age subgroup following initiation of paroxetine therapy: a complete set of randomized placebo-controlled trials.
    Carpenter DJ, Fong R, Kraus JE, Davies JT, Moore C, Thase ME.
    J Clin Psychiatry; 2011 Nov; 72(11):1503-14. PubMed ID: 21367354
    [Abstract] [Full Text] [Related]

  • 18. Relationship between depression severity entry criteria and antidepressant clinical trial outcomes.
    Khan A, Schwartz K, Kolts RL, Ridgway D, Lineberry C.
    Biol Psychiatry; 2007 Jul 01; 62(1):65-71. PubMed ID: 17141744
    [Abstract] [Full Text] [Related]

  • 19. Anxiety does not predict response to duloxetine in major depression: results of a pooled analysis of individual patient data from 11 placebo-controlled trials.
    Nelson JC.
    Depress Anxiety; 2010 Jul 01; 27(1):12-8. PubMed ID: 20013987
    [Abstract] [Full Text] [Related]

  • 20. Meta-analysis of placebo rates in major depressive disorder trials.
    Stolk P, Ten Berg MJ, Hemels ME, Einarson TR.
    Ann Pharmacother; 2003 Dec 01; 37(12):1891-9. PubMed ID: 14632596
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.